JP2021512133A5 - - Google Patents
Info
- Publication number
- JP2021512133A5 JP2021512133A5 JP2020542296A JP2020542296A JP2021512133A5 JP 2021512133 A5 JP2021512133 A5 JP 2021512133A5 JP 2020542296 A JP2020542296 A JP 2020542296A JP 2020542296 A JP2020542296 A JP 2020542296A JP 2021512133 A5 JP2021512133 A5 JP 2021512133A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- bacteria
- item
- veillonella
- accession number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862626789P | 2018-02-06 | 2018-02-06 | |
| US62/626,789 | 2018-02-06 | ||
| US201862666944P | 2018-05-04 | 2018-05-04 | |
| US62/666,944 | 2018-05-04 | ||
| US201862703269P | 2018-07-25 | 2018-07-25 | |
| US62/703,269 | 2018-07-25 | ||
| PCT/US2019/016763 WO2019157003A1 (en) | 2018-02-06 | 2019-02-06 | Compositions and methods for treating cancer and immune disorders using veillonella bacteria |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512133A JP2021512133A (ja) | 2021-05-13 |
| JP2021512133A5 true JP2021512133A5 (enExample) | 2022-02-15 |
| JP7402805B2 JP7402805B2 (ja) | 2023-12-21 |
Family
ID=65767281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542296A Active JP7402805B2 (ja) | 2018-02-06 | 2019-02-06 | ベイロネラ（Ｖｅｉｌｌｏｎｅｌｌａ）の細菌を使用して癌及び免疫障害を処置するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11090341B2 (enExample) |
| EP (1) | EP3749340A1 (enExample) |
| JP (1) | JP7402805B2 (enExample) |
| KR (1) | KR20200118100A (enExample) |
| CN (1) | CN112074283A (enExample) |
| AU (1) | AU2019217526A1 (enExample) |
| BR (1) | BR112020015639A2 (enExample) |
| CA (1) | CA3090166A1 (enExample) |
| CO (1) | CO2020010956A2 (enExample) |
| MX (1) | MX2020008244A (enExample) |
| SA (1) | SA520412543B1 (enExample) |
| TW (1) | TW201945015A (enExample) |
| WO (1) | WO2019157003A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017100420A1 (en) * | 2015-12-08 | 2017-06-15 | Mayo Foundation For Medical Education And Research | Biomarkers for predicting clostridium difficile infection treatment outcome |
| IL265109B2 (en) | 2016-09-13 | 2024-05-01 | Allergan Inc | Stabilized non-protein clostridial toxin compositions |
| TW202045192A (zh) * | 2019-02-22 | 2020-12-16 | 美商艾弗洛生物科技股份有限公司 | 細菌膜製劑 |
| WO2021142279A1 (en) * | 2020-01-10 | 2021-07-15 | Evelo Biosciences, Inc. | Compositions and methods of treatment using veillonella parvula |
| CN115551486A (zh) * | 2020-04-17 | 2022-12-30 | 伊夫罗生物科学公司 | 具有改善的崩解谱的固体剂型 |
| CN114796264A (zh) * | 2021-01-27 | 2022-07-29 | 北京北工大科技园有限公司 | 金络合物在制备治疗新型冠状病毒肺炎的药物中的应用 |
| WO2022051494A1 (en) * | 2020-09-03 | 2022-03-10 | Evelo Biosciences, Inc. | Compositions and methods for resolution of inflammation |
| TW202233214A (zh) | 2020-11-06 | 2022-09-01 | 美商艾弗洛生物科技股份有限公司 | 使用小韋榮氏球菌細菌誘導免疫效應 |
| JP2024501481A (ja) | 2020-12-14 | 2024-01-12 | エヴェロ バイオサイエンシズ，インコーポレーテッド | 細胞外小胞調製物 |
| WO2022191183A1 (ja) * | 2021-03-08 | 2022-09-15 | 学校法人順天堂 | 炎症抑制作用を有する組成物及び改善剤 |
| TW202304415A (zh) * | 2021-04-08 | 2023-02-01 | 美商艾弗洛生物科技股份有限公司 | 含有細菌的藥物製劑 |
| WO2023062422A1 (en) * | 2021-10-11 | 2023-04-20 | Vastu Vihar Biotech Private Limited | An anti-inflammatory composition and a method of obtaining the same |
| KR102859962B1 (ko) * | 2021-10-20 | 2025-09-18 | 주식회사 고바이오랩 | 항암 활성을 갖는 베일로넬라 파르불라 균주를 이용한 암의 완화, 예방 또는 치료용 조성물 |
| WO2023114300A1 (en) | 2021-12-14 | 2023-06-22 | Evelo Biosciences, Inc. | Fournierella massiliensis bacteria extracellular vesicle preparations |
| WO2023114295A1 (en) | 2021-12-14 | 2023-06-22 | Evelo Biosciences, Inc. | Veillonella parvula bacteria extracellular vesicle preparations |
| CN114146098A (zh) * | 2021-12-31 | 2022-03-08 | 中山大学 | Veillonella atypica在制备预防和/或治疗结直肠癌药物中的应用 |
| WO2023146843A1 (en) | 2022-01-25 | 2023-08-03 | Evelo Biosciences, Inc. | Extracellular vesicle compositions and methods of use |
| WO2023234587A1 (ko) * | 2022-05-30 | 2023-12-07 | 한국생명공학연구원 | 베일로넬라 세미날리스 균주, 그의 유래의 배양액 및 그의 항염증 용도 |
| KR102861997B1 (ko) * | 2022-05-30 | 2025-09-22 | 한국생명공학연구원 | 베일로넬라 세미날리스 균주, 그의 유래의 배양액 및 그의 항염증 용도 |
| CN116355785A (zh) * | 2022-09-29 | 2023-06-30 | 南京市儿童医院 | 一株小韦荣氏球菌及其在制备诊断和治疗口腔鳞状细胞癌产品中的应用 |
| CN115990260B (zh) * | 2022-12-09 | 2025-07-22 | 中国药科大学 | 一种用于抗肿瘤的联用组合药物 |
| EP4658287A1 (en) * | 2023-01-30 | 2025-12-10 | MRM Health N.V. | Microbial compositions for treating joint inflammation |
| TWI859033B (zh) * | 2023-12-18 | 2024-10-11 | 安益藥業股份有限公司 | 一種診斷犬科動物胰臟炎的方法與試劑組與一種使用醯基肉鹼作為診斷犬科動物胰臟炎之用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57139090A (en) * | 1981-02-19 | 1982-08-27 | Toyama Chem Co Ltd | Carcinostatic substance tv-110, its preparation and carcinostatic agent containing the same |
| JPH04330016A (ja) * | 1991-05-01 | 1992-11-18 | Rikagaku Kenkyusho | 過酸化脂質低下剤 |
| US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| EP0991761B1 (en) * | 1997-08-21 | 2008-01-16 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Novel mutants of gram negative mucosal bacteria and application thereof in vaccines |
| GB0130123D0 (en) | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
| WO2004069156A2 (en) * | 2003-01-30 | 2004-08-19 | The Regents Of The University Of California | Inactivated probiotic bacteria and methods of use thereof |
| CA2571805C (en) * | 2006-10-27 | 2018-05-01 | Harold David Gunn | Tissue targeted antigenic activation of the immune response to cancers |
| US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| AU2014239883B2 (en) | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| WO2015038731A1 (en) * | 2013-09-12 | 2015-03-19 | The Johns Hopkins University | Biofilm formation to define risk for colon cancer |
| WO2015095241A2 (en) * | 2013-12-16 | 2015-06-25 | Seres Health, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
| WO2016040074A1 (en) * | 2014-09-11 | 2016-03-17 | Drexel University | Maximizing production of hydrogen from waste materials by active removal of hydrogen |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| SE1550189A1 (en) * | 2015-02-19 | 2016-08-20 | Achim Biotherapeutics Ab | Therapeutic and prophylactic composition produced by microbiota |
| WO2016141454A1 (en) * | 2015-03-12 | 2016-09-15 | The University Of British Columbia | Bacterial compositions and methods of use thereof |
| KR101734653B1 (ko) * | 2015-06-23 | 2017-05-11 | 서울대학교산학협력단 | 아미노글리코시드계 항생제 및 프로바이오틱스를 포함하는 아프타 구내염 예방 또는 치료용 약학적 조성물 |
| CN111148531A (zh) * | 2017-09-08 | 2020-05-12 | 伊夫罗生物科学公司 | 细菌胞外囊泡 |
| WO2020252144A1 (en) * | 2019-06-11 | 2020-12-17 | Evelo Biosciences, Inc. | Secreted microbial extracellular vesicles |
-
2019
- 2019-02-06 KR KR1020207025184A patent/KR20200118100A/ko not_active Withdrawn
- 2019-02-06 JP JP2020542296A patent/JP7402805B2/ja active Active
- 2019-02-06 BR BR112020015639-6A patent/BR112020015639A2/pt not_active IP Right Cessation
- 2019-02-06 AU AU2019217526A patent/AU2019217526A1/en not_active Abandoned
- 2019-02-06 CA CA3090166A patent/CA3090166A1/en active Pending
- 2019-02-06 MX MX2020008244A patent/MX2020008244A/es unknown
- 2019-02-06 US US16/268,745 patent/US11090341B2/en not_active Expired - Fee Related
- 2019-02-06 WO PCT/US2019/016763 patent/WO2019157003A1/en not_active Ceased
- 2019-02-06 EP EP19711177.6A patent/EP3749340A1/en not_active Withdrawn
- 2019-02-06 CN CN201980011880.3A patent/CN112074283A/zh active Pending
- 2019-02-11 TW TW108104512A patent/TW201945015A/zh unknown
-
2020
- 2020-07-29 SA SA520412543A patent/SA520412543B1/ar unknown
- 2020-10-05 CO CONC2020/0010956A patent/CO2020010956A2/es unknown
-
2021
- 2021-07-06 US US17/368,396 patent/US20210330718A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502964A5 (enExample) | ||
| JP2020526581A5 (enExample) | ||
| JP7254786B2 (ja) | ビフィドバクテリウム・アニマリス亜種ラクティス（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ ａｎｉｍａｌｉｓ ｓｓｐ．ｌａｃｔｉｓ）を用いて癌を処置するための組成物及び方法 | |
| CN111225675B (zh) | 使用过继细胞疗法治疗的制品和方法 | |
| EP3894013A1 (en) | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent | |
| JP2021512133A (ja) | ベイロネラ（Ｖｅｉｌｌｏｎｅｌｌａ）の細菌を使用して癌及び免疫障害を処置するための組成物及び方法 | |
| JP2019536793A5 (enExample) | ||
| US12291559B2 (en) | Compositions and methods for treating cancer | |
| JP2019500012A5 (enExample) | ||
| KR20220081909A (ko) | 액체 약학적 조성물에서 매우 안정한 치료적으로 활성인 알데스루킨 | |
| JP2015508816A (ja) | Ｏｘ４０アゴニスト／ｉｌ−２二重癌治療法 | |
| JP2023071724A (ja) | Ｃｍｖエピトープ | |
| US20240102047A1 (en) | An oncolytic virus vector coding for variant interleukin-2 (vIL-2) polypeptide | |
| CN113906140A (zh) | A2/ny-eso-1特异性t细胞受体及其用途 | |
| JP2023522018A (ja) | 改善された崩壊プロファイルを有する固形剤形 | |
| JP2026031931A (ja) | 標的化ｅｐｈａ３及びその使用 | |
| KR20210013592A (ko) | Cmv 감염 및 cmv-관련 질환에 대한 적응 t-세포 치료법 | |
| WO2019075452A1 (en) | IDENTIFICATION OF BACTERIA FOR CANCER THERAPY | |
| US20240398986A1 (en) | An oncolytic virus vector coding for interleukin-7 (IL-7) polypeptide | |
| HK40104233A (zh) | 编码白细胞介素-7(il-7)多肽的溶瘤病毒载体 | |
| Zhangh et al. | Haijing Denga, b Anna Kana, c Ning Lyua, b Luwen Mud Yi Hana Longzhong Liua, e Yanyu Zhanga Youfa Duana Shuangye Liaoa Shaolong Lia Qiankun Xiea, f Tianxiao Gaoa, g Yanrong Lia, b | |
| Brance | Rapid responses to golimumab in refractory adult-onset Still's disease: A case report and review of the literature | |
| Montorfani | Activation sélective de la signalisation interleukine-2/interleukine-15 dans le microenvironnement tumoral par des paires d’anticorps bispécifiques | |
| Küpper | Analysis of T cells as potential sources of interleukin-22 in colorectal cancer | |
| Küpper | Aus der Abteilung für Klinische Pharmakologie Leiter: Prof. Dr. med. S. Endres |